Cytek Biosciences (CTKB) to Release Earnings on Wednesday

Cytek Biosciences (NASDAQ:CTKB) is expected to be releasing its Q2 2025 earnings data after the market closes on Wednesday, August 6th. Analysts expect Cytek Biosciences to post earnings of ($0.02) per share and revenue of $46.03 million for the quarter. Cytek Biosciences has set its FY 2025 guidance at EPS.

Cytek Biosciences (NASDAQ:CTKB) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.05). The company had revenue of $41.46 million during the quarter, compared to analysts’ expectations of $43.18 million. Cytek Biosciences had a negative return on equity of 2.90% and a negative net margin of 5.71%.

Cytek Biosciences Trading Up 1.1%

Shares of CTKB opened at $3.64 on Monday. The business’s 50-day moving average price is $3.29 and its 200 day moving average price is $3.93. The stock has a market capitalization of $461.04 million, a P/E ratio of -40.44 and a beta of 1.34. Cytek Biosciences has a 1-year low of $2.37 and a 1-year high of $7.63.

Insider Buying and Selling at Cytek Biosciences

In other news, CFO William D. Mccombe purchased 35,000 shares of the business’s stock in a transaction dated Monday, June 2nd. The stock was bought at an average cost of $2.78 per share, with a total value of $97,300.00. Following the purchase, the chief financial officer directly owned 55,746 shares of the company’s stock, valued at approximately $154,973.88. This trade represents a 168.71% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 10.33% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cytek Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Strs Ohio purchased a new stake in shares of Cytek Biosciences during the 1st quarter worth about $105,000. Acadian Asset Management LLC purchased a new stake in shares of Cytek Biosciences during the 1st quarter worth about $162,000. Jane Street Group LLC raised its stake in shares of Cytek Biosciences by 412.2% during the 1st quarter. Jane Street Group LLC now owns 344,169 shares of the company’s stock worth $1,380,000 after purchasing an additional 276,972 shares in the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of Cytek Biosciences by 394.4% during the 1st quarter. AQR Capital Management LLC now owns 653,277 shares of the company’s stock worth $2,620,000 after purchasing an additional 521,135 shares in the last quarter. 69.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on CTKB. The Goldman Sachs Group decreased their price objective on Cytek Biosciences from $3.50 to $3.00 and set a “sell” rating for the company in a research report on Monday, May 12th. TD Cowen lowered Cytek Biosciences from a “buy” rating to a “hold” rating and set a $4.00 price objective for the company. in a research report on Friday, May 9th. Finally, Morgan Stanley decreased their price objective on Cytek Biosciences from $9.00 to $7.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 28th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $5.60.

About Cytek Biosciences

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.